Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective

Surrogate end point only is not enough-the Swiss regulator`s perspective on (neo)adjuvant trials.

Automated summary

The Swiss regulator emphasizes the insufficiency of relying solely on surrogate endpoints in (neo)adjuvant trials, highlighting the need for a more comprehensive evaluation.